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Summary
Background. So far few studies have focused on the last steps of drug-use trajectories. Heroin has been described as a 
final stage, but the non-medical use of prescription opioids (NMUPOs) is often associated with heroin use. There is, how-
ever, no consensus yet about which one precedes the other. Aims. The objective of this study was to test which of these 
two substances was likely to be induced by the other using a prospective design. Material and methods. We used data 
from the Swiss Longitudinal Cohort Study on Substance Use Risk Factors (C-SURF) to assess exposure to heroin and 
NMUPO at two times points (N = 5,041). Cross-lagged panel models provided evidence regarding prospective pathways 
between heroin and NMUPOs. Power analyses provided evidence about significance and clinical relevance. Results. 
Results showed that heroin use predicted later NMUPO use (β = 1.217, p < 0.001) and that the reverse pathway was 
non-significant (β = 0.240, p = .233). Heroin use seems to be an important determinant, causing a 150% risk increase for 
NMUPO use at follow-up, whereas NMUPO use at baseline increases the risk of heroin use at follow-up by a mere non-
significant 20%. Conclusions. Thus, heroin users were more likely to move to NMUPOs than non-heroin users, whereas 
NMUPO users were not likely to move to heroin use. The pathway of substance use seemed to include first heroin use, 
then NMUPO use.
Key Words: Drug use; longitudinal study; population-based sample.
1.  Introduction
Involvement in drug use has to be a focus of at-
tention because drug use is especially harmful and is 
responsible for a heavy burden of disease all over the 
world. The sequential stages of involvement in drug 
use is a commonly agreed model in modern Western 
societies [14, 19-21, 34], and heroin is often described 
as a final stage drug in the drug-use trajectory [1, 38, 
39]. Heroin users are also known to be extensive users 
of non-medical use prescription drugs (i.e. the use of 
prescription drugs without a prescription or in ways 
not recommended by a doctor [3, 17, 22, 27]). Several 
studies investigating heroin users’ non-medical use of 
prescription drugs have focused on non-medical use 
prescription opioids (NMUPOs), as these two kinds 
of substances may be used alternatively with similar 
effects. A conventional trajectory shows that NMU-
POs act as substitutes for heroin; thus their use occurs 
a certain time after heroin initiation [8, 11, 16]. Some 
recent studies have, however, reported trajectories of 
misuse and dependence starting with NMUPOs and 
then moving on to heroin [7, 13, 24, 31, 32, 35]. Thus, 
causal pathways between heroin and NMUPO still 
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call for clarification.
Moreover, several other methodological issues 
should be highlighted. First, previous studies focus-
ing on the correlates of heroin use and NMUPOs 
mostly included all injectable-drug users (i.e. not fo-
cusing on heroin users alone) [24, 27] or heroin users 
engaged in methadone maintenance treatment [9, 26, 
35], using syringe-exchange services [31] or conven-
ience samples/respondents driven samples of heavy 
drug users [6, 10, 30]. Studies focusing on general 
pathways from population-based samples are still too 
few, and one can wonder about the common path for 
“occasional” or “experimental” heroin users who 
represent 90-95% of drug users [23]. Second, to our 
knowledge, all these studies took place in the United 
States. The likelihood of drug use depends on several 
factors, including contextual and cultural factors such 
as availability, opportunities or norms [5, 25]. For ex-
ample, one common, well-studied prescription opioid 
in the United States is OxyContin®, which was refor-
mulated in late 2010. The new formulation made Ox-
yContin more difficult to manipulate for abuse than 
the older one [6, 15, 29], and some individuals who 
had previously abused OxyContin switched to her-
oin thereafter. This phenomenon may have induced 
an artifact impression of NMUPOs as a category of 
gateway drugs for heroin use, as described in recent 
US studies [7, 24, 31, 32]. Studies in other countries, 
especially in Europe, are too few in number. Lastly, 
most of these studies have a cross-sectional design. 
The questionnaires include questions about the first 
use of heroin and NMUPOs, but in a retrospective 
way. This procedure may be associated with in-
creased bias, such as recall bias. Prospective studies 
are needed to study how drug users start to use drugs 
and the paths between one and another.
Thus, the aim of the present study has been to 
give some insight into stages of drug use involving 
heroin use and NMUPOs within a population-based 
sample of young Swiss men. Prospective pathways 
between heroin and NMUPOs were tested to identify 
which substance increased the likelihood of succes-
sive use of the other.
2.  Materials and methods
2.1. Participants and procedures
We used data from the Cohort Study on Sub-
stance Use Risk Factors (C-SURF), a longitudinal 
study designed to assess substance use patterns in 
young Swiss men. Participants were enrolled in three 
of Switzerland’s six army recruitment centres, cov-
ering 21 of the country’s 26 cantons and located in 
(French-speaking) Lausanne, and in (German-speak-
ing) Windisch and Mels. As army recruitment is com-
pulsory in Switzerland, and there is no pre-selection 
for conscription, all young men around 20 years old 
were eligible for study inclusion. We carried out as-
sessment outside the army environment and inde-
pendently of eligibility for military service. Partici-
pants who gave their written consent to participate in 
recruitment centres were invited two weeks later by 
mail or email to fill in a pen-and-paper or an online 
questionnaire, according to the favourite way indicat-
ed by them in the written consent form. For follow-
up, all the participants were similarly invited to fill 
in the questionnaire, by mail or email. We collected 
baseline data between September 2010 and March 
2012, and follow-up data between January 2012 and 
April 2013. A total of 5,990 participants filled in the 
baseline questionnaire, and 5,223 (87.2%) filled in 
the follow-up questionnaire. Missing values were list-
wise deleted, and the final sample consisted of 5,041 
participants (96.5% of the follow-up sample). Studer 
et al. [37] gave more information on sampling and 
non-response. Put briefly, non-respondents were most 
likely substance users, but the non-response bias was 
small. Lausanne University Medical School’s Clini-
cal Research Ethics Committee approved the study 
protocol (Protocol No. 15/07).
2.2. Measures
2.2.1. Heroin use. 
We assessed heroin use by asking participants 
whether they had used heroin during the previous 
twelve months, both at baseline and then at follow-
up. Answers were collected on a three-point scale 
(“never”, “1-3 times”, “4 times or more”), and re-
coded as ‘used’ or ‘not used’ because heavier use was 
very rare in the sample.
2.2.2. Non-medical use prescription opioids (NMUPOs). 
We assessed the use of prescription opioids 
without a doctor’s prescription or for reasons other 
than those indicated, during the previous twelve 
months, both at baseline and follow-up. The answers 
were collected on an eight-point scale (“never”, “1 
time/year”, “2-3 times/year”, “4-9 times/year”, “1-2 
times/month”, “3-4 times/month”, “2-3 times/week”, 
“4 times or more/week”) and recoded dichotomously 
as ‘used’ or ‘not used’, because heavy or even regular 
use was rare in the sample. The question dealt with 
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“strong painkillers”: “e.g. based on Buprenorphine 
(Tamgesic®), Codeine (Benylin®), or opium-based 
products (Fentanyl, Hydrocodon, Jurnista®, Palla-
don®, Targin®, Oxycontin®, Vicodin®, Dilaudid®) 
or DXM (Bexin®) (not mere painkillers such as Aspi-
rin or Paracetamol).” Thus, over-the-counter painkill-
ers were excluded.
2.2.3. Use of other drugs. 
We also assessed the use, over the previous 
12 months, of other illicit drugs (i.e. cannabis, hal-
lucinogens, salvia divinorum, speed, amphetamine, 
methamphetamine, crystal meth, poppers, solvents 
for sniffing, ecstasy, cocaine, ketamine, research 
chemicals, and spice) and of non-medical use of 
other prescription drugs: sleeping pills (e.g. Benzo-
diazepine (Dalmadorm®, Rohypnol®, Halcion®), 
Barbiturate, Chloralhydrate (Nervifene®), zopiclon, 
zolpidem (Imovane®, Stilnox®)), tranquilizers (e.g. 
Benzodiazepine (Valium®, Xanax®, Librax®, Te-
mesta®, Normison®, Demetrin®, Dalmadorm®) or 
muscle-relaxing products), stimulants (e.g. Ampheta-
minsulphate (Aderall), Atomoxetine (Strattera®), 
Methylphenidate (Ritalin®)), antidepressants (Re-
meron®, Fluoxetine®, Citalopram®, Trimin®), and 
beta blockers (e.g. Propranolol (Inderal®), Atenolol 
(Atenil®, Tenormin®), Metoprolol (Lopresor®)). We 
computed four overall variables to cover the use of 
other drugs: 1) illicit drug use at baseline, 2) illicit 
drug use at follow-up, 3) non-medical use of prescrip-
tion drugs at baseline, and 4) non-medical use of pre-
scription drugs at follow-up. Each variable was coded 
dichotomously as ‘used’ if at least one drug of the 
class was used, or ‘not used’ otherwise.
Drug use was assessed using the standards of the 
European Monitoring Centre for Drugs and Drug Ad-
diction (EMCDAD, see for example [10]).
2.3. Statistical analyses
We first calculated descriptive statistics to see 
the prevalence rate of heroin and NMUPO users 
within the sample. Then, we used cross-lagged pan-
els models to test the predominant causal influence 
between heroin and NMUPO. The model included 
a) autoregression (i.e. regression between the same 
variable at baseline and follow-up), b) synchronous 
correlations (i.e. correlations between different vari-
ables at the same time point), c) causal paths with 
cross-lagged paths from heroin use to NMUPO, 
and d) reverse-causal paths with cross-lagged paths 
from NMUPO to heroin use. We used probit regres-
sions with theta parameterization including a robust 
weighted least squares estimator (WLSMV). Due to 
low sample size, the model had to be tested by check-
ing the following variables one by one: age, other il-
licit drug use, and non-medical use of other prescrip-
tion drugs. To test whether the low sample size of 
heroin users led to a lack of power, we also performed 
power analyses. Simulation studies were carried out 
using non-parametric bootstrap in order to estimate 
achieved power for detecting significant relationships 
for various sample sizes. All statistical examinations 
were carried out using Mplus 7 [30] and R (2014).
3. Results
The mean age of the participants was 19.97 ± 
1.22 years at baseline and 21.26 ± 1.23 years at fol-
low-up. Around 15 months separated baseline data 
collection from follow-up data collection. 
Descriptive statistics are shown in Table 1. A mi-
nority of the participants used heroin both at baseline 
(0.3%) and follow-up (0.8%). NMUPO had a higher 
prevalence rate, with 6.5% of users at baseline and 
6.1% of users at follow-up.
Figure 1 presents the cross-lagged model test-
ing the prospective pathways between heroin use 
and NMUPOs. Each drug at baseline significantly 
predicted the level of the same drug at follow-up: 
heroin use at baseline predicted heroin use at follow-
up (β=2.216, p<0.001, 5.7-fold risk increase, pow-
er=100%), while NMUPO use at baseline predicted 
NMUPO use at follow-up (β=1.006, p<0.001, 2.1-
fold risk increase, power=100%) Moreover, heroin 
use at baseline predicted NMUPO use at follow-up 
Table 1. Prevalence rates of drug use
Baseline, % (N) Follow-up, % (N)
Heroin 0.3 (16) 0.8 (38)
Non-medical use of prescription opioids 6.65 (327) 6.1 (306)
Other illicit drugs 32.4 (1,631) 33.4 (1,685)
Non-medical use of other prescription drugs 10.4 (525) 9.5 (479)
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(β=1.217, p<0.001, 2.5-fold increase, power=93%), 
but the reverse-causal path from NMUPO to heroin 
use was non-significant (β=0.240, p=0.233, 1.2-fold 
risk increase, power=26%, number of participants 
needed for a power=90%: 45,000). Adjustment by 
the previously mentioned covariates did not yield any 
significant change.
4. Discussion
This study aimed to give some insight into the 
stages of drug use involving use of heroin and NMU-
POs within a large population-based sample of young 
Swiss men.
Heroin use was a problem in a minority of the 
sample, as less than 1% used heroin. On the other 
hand, NMUPO use was more frequent, as over 6% 
used opioids without a doctor’s prescription. This re-
sult is in line with previous studies reporting opioids 
and painkillers as being the most common substances 
used after alcohol, tobacco, and cannabis [4, 12, 18, 
28].
Prospective pathways showed that heroin us-
ers were more likely to start using an NMUPO, but 
not the reverse: NMUPO users were not significantly 
more prone to start using heroin. Indeed, cross-lagged 
panel models showed a causal path between heroin 
and NMUPO use, but not the reversed causal path. 
For this last path, the power analysis allowed the test-
ing of whether there was a lack of significance due to 
low sample size. The results of the simulation study 
showed that our sample size yields a 26% power for 
detecting such an effect. If such a link exists, a sam-
ple size of 45,000 participants would be required 
to achieve a 90% power. It did not seem therefore, 
that the non-significant result was due to a lack of 
power. Moreover, even if there was a causal relation-
ship between NMUPOs and later heroin use, this 
link remained marginal. Indeed, heroin use at base-
line raised the risk of NMUPO use at follow-up by a 
nearly 2.5-fold factor, whereas NMUPO use at base-
line was found to be of only marginal importance on 
heroin at follow-up (a 1.2-fold risk increase). There-
fore, the clinical relevance of the relation between 
NMUPO use at baseline and heroin use at follow-up 
is questionable: NMUPO use at baseline increases the 
risk of heroin use at follow-up by a mere 20%, while 
in the reverse pathway, heroin use seems to be an im-
portant determinant, causing a 150% risk increase for 
NMUPO use at follow-up.
The main determinant of heroin use at follow-up 
appeared to be the use of heroin at baseline (470%). 
As a result, the main trajectory for heroin users was to 
continue to use heroin, and additionally to start using 
NMUPOs (150%), but not to have started initially with 
NMUPOs (20%). By contrast, there were opioid us-
Figure 1. Cross-lagged model examining the associations between heroin use and non-medical use of 
prescription opioids. (In the interests of clarity, this figure only presents significant cross-lagged paths. 
However, all the cross-lagged paths depicted in Figure 1 were included in the final model (within-time 
correlations between variables at both Time 1 and Time 2 and path from NMUPO to heroin use)). 
*** p < .001.
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21.26 at follow-up, had not yet experienced heroin. 
Another shortcoming was that the study focused on 
substance use (i.e. use at least one time in the pre-
vious twelve months versus non-use). Studies in the 
US often deal with abuse and dependence. Therefore, 
further studies should include measures of frequency 
of use and misuse in order to identify users who will 
later develop problematic use. That procedure would 
allow testing whether the pathway identified for sub-
stance use also fits substance misuse and dependence. 
The 15-month follow-up was quite short in terms of 
the adequate assessment of such trajectories. Finally, 
we do not know whether NMUPOs were used by our 
participants to ‘get high’ or as self-medication; thus 
further research is now needed to investigate the rea-
sons for use, and why users switched from heroin to 
an NMUPO.
5. Conclusion
In conclusion, this study yielded insights into 
the final stages of involvement in drug use in a pop-
ulation-based sample. Clinically relevant prospective 
pathways go from previous heroin use to continued 
heroin use and starting NMUPO use, whereas previ-
ous NMUPO use leads only to continuing with NMU-
POs. The contexts in which drug users are embedded 
are especially important in acquiring an understand-
ing of trajectories in drug course and paths from one 
drug to another. Contextual information should be 
included in studies focusing on sequential stages of 
involvement in drug use.
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